Differential proteomic analysis of endemic and sporadic Epstein-Barr virus-positive and negative Burkitt lymphoma.

[1]  L. Staudt,et al.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.

[2]  A. Rosenwald,et al.  The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma , 2011, Leukemia.

[3]  W. N. Chen,et al.  Proteome profiling of Epstein-Barr virus infected nasopharyngeal carcinoma cell line: identification of potential biomarkers by comparative iTRAQ-coupled 2D LC/MS-MS analysis. , 2011, Journal of proteomics.

[4]  S. Pileri,et al.  Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. , 2010, Blood.

[5]  W. Sanger,et al.  Comparative Genomic Identification of Unique Signal Transduction Pathways and Targets In Pediatric Burkitt Lymphoma (PBL) , 2010 .

[6]  S. Perkins,et al.  The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling , 2010, Leukemia.

[7]  P. Szankasi,et al.  The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. , 2009, Blood.

[8]  Yong‐Nyun Kim,et al.  The heat‐shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein–Barr virus‐positive NK/T‐cell lymphoma by Akt down‐regulation , 2007, The Journal of pathology.

[9]  K. Elenitoba-Johnson,et al.  Proteome‐wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells , 2007, Proteomics.

[10]  B. Efron.  Correlation and Large-Scale Simultaneous Significance Testing , 2007 .

[11]  A. Rickinson,et al.  Three restricted forms of Epstein–Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells , 2006, Proceedings of the National Academy of Sciences.

[12]  M. Wahlgren,et al.  Increased B Cell Survival and Preferential Activation of the Memory Compartment by a Malaria Polyclonal B Cell Activator1 , 2006, The Journal of Immunology.

[13]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[14]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[15]  B. Torok-Storb,et al.  Monocyte-derived CXCL7 peptides in the marrow microenvironment. , 2006, Blood.

[16]  Bin Chen,et al.  The HSP90 family of genes in the human genome: insights into their divergence and evolution. , 2005, Genomics.

[17]  M. Bourgeade,et al.  EBV Infection of Human B Lymphocytes Leads to Down-Regulation of Bim Expression: Relationship to Resistance to Apoptosis1 , 2005, The Journal of Immunology.

[18]  W. Hammerschmidt,et al.  Epstein-Barr Virus Nuclear Antigen 2 (EBNA2) Gene Deletion Is Consistently Linked with EBNA3A, -3B, and -3C Expression in Burkitt's Lymphoma Cells and with Increased Resistance to Apoptosis , 2005, Journal of Virology.

[19]  Adam A. Margolin,et al.  Reverse engineering of regulatory networks in human B cells , 2005, Nature Genetics.

[20]  H. Stuhlmann,et al.  CD98hc (SLC3A2) mediates integrin signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. V. D. Bosch,et al.  Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter? , 2004 .

[22]  K. Elenitoba-Johnson,et al.  Proteomics in pathology research , 2004, Laboratory Investigation.

[23]  Robertson Craig,et al.  TANDEM: matching proteins with tandem mass spectra. , 2004, Bioinformatics.

[24]  B. Sugden,et al.  Epstein-Barr virus provides a survival factor to Burkitt's lymphomas , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[26]  L. Neckers,et al.  Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.

[27]  F. Martinon,et al.  RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF‐κB and is processed during apoptosis , 2002, EMBO reports.

[28]  M. Lindström,et al.  Role of genetic and epigenetic changes in Burkitt lymphoma. , 2002, Seminars in cancer biology.

[29]  A. Nanbo,et al.  Epstein–Barr virus RNA confers resistance to interferon‐α‐induced apoptosis in Burkitt's lymphoma , 2002 .

[30]  J. Sample,et al.  Epstein-Barr Virus Small RNAs Potentiate Tumorigenicity of Burkitt Lymphoma Cells Independently of an Effect on Apoptosis , 2000, Journal of Virology.

[31]  R. Passantino,et al.  ENO1 gene product binds to the c‐myc promoter and acts as a transcriptional repressor: relationship with Myc promoter‐binding protein 1 (MBP‐1) , 2000, FEBS letters.

[32]  S. Maruo,et al.  Oncogenic Role of Epstein-Barr Virus-Encoded RNAs in Burkitt’s Lymphoma Cell Line Akata , 1999, Journal of Virology.

[33]  T. Tursz,et al.  Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells , 1998, Oncogene.

[34]  K. Bhatia,et al.  Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. , 1997, Cancer research.

[35]  S. Matsuoka,et al.  D-type cyclin-binding regions of proliferating cell nuclear antigen. , 1994, The Journal of biological chemistry.

[36]  C. Kittas,et al.  p53, c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas. , 1994, Journal of clinical pathology.

[37]  P. Levine,et al.  Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. , 1991, Blood.

[38]  A. Rickinson,et al.  Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. , 2007, Hematology. American Society of Hematology. Education Program.